K 23 with Emphasis on Therapeutic Interventions Employing Genomic or Proteomic Technologies
The summary for the K 23 with Emphasis on Therapeutic Interventions Employing Genomic or Proteomic Technologies grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
K 23 with Emphasis on Therapeutic Interventions Employing Genomic or Proteomic Technologies: - The program will support clinicians who propose an integrated clinical research and bench research project that applies genomics and proteomics tools to the study of human patients whose disease has a genetic component. - The anticipated number of awards is between four and six. - The K 23 mechanism will be used. - Eligible organizations include for-profit or non-profit organizations, public or private institutions, units of State and local governments or eligible agencies of the Federal government. Foreign institutions are not eligible to apply.. - Eligible principal investigators include candidate who must have a clinical doctoral degree or its equivalent, must have completed clinical training, must identify a mentor with extensive research experience in clinical research and genomics or proteomics and must be willing and able to spend a minimum of 90% of full-time professional effort in support of this award. - At the time of the award, a candidate must be a citizen or non-citizen national of the United States, or have been lawfully admitted to the United States for permanent residence (i.e., in possession of a currently valid Alien Registration Receipt Card I-551, or other legal verification of such status). - Each applicant may submit only one application. - The PHS 398 application materials are available at http://grants.nih.gov/grants/funding/phs398/phs398.html. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088.
Federal Grant Title: | K 23 with Emphasis on Therapeutic Interventions Employing Genomic or Proteomic Technologies |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Health Education |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-HG-05-013 |
Type of Funding: | Grant |
CFDA Numbers: | 93.17293.279 |
CFDA Descriptions: | Human Genome Research 93.279 Drug Abuse Research Programs |
Current Application Deadline: | No deadline provided |
Original Application Deadline: | Jun 15, 2005 |
Posted Date: | Jan 18, 2005 |
Creation Date: | Jan 18, 2005 |
Archive Date: | Jul 15, 2005 |
Total Program Funding: | $1,000,000 |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | 4 |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education State governments Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Additional Information on Eligibility
- Foreign institutions are not eligible to apply.
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster